Results 21 to 30 of about 24,516 (282)

A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome

Children, 2022
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab.
Saeed AlZabali, Sawsan AlBatati, Khawla Rahim, Hassan Faqeehi, Abubaker Osman, Abdulaziz Bamhraz, Mohammed A. Saleh, Jameela A. Kari, Majed Aloufi, Loai Eid, Haydar Nasser, Abubakr Imam, Entesar AlHammadi, Omar Alkandari, Mohammed Al Riyami, Sidharth Sethi, Christoph Licht, Khalid A. Alhasan, Abdulkarim AlAnazi   +18 more
doaj   +1 more source

Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report

Case Reports in Neurology, 2021
The recombinant humanized monoclonal antibody eculizumab has been shown to be effective and well tolerated in patients with anti-acetylcholine receptor antibody-positive, treatment-refractory generalized myasthenia gravis (gMG).
Tuan Vu, Brittany Harvey, Niraja Suresh, Jerrica Farias, Clifton Gooch   +4 more
doaj   +1 more source

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

New England Journal of Medicine, 2013
Denis Fouque, Bruno Moulin, Giuseppe Remuzzi   +2 more
exaly   +2 more sources

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient

Frontiers in Immunology, 2021
BackgroundWith the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS).
Romy N. Bouwmeester, Mendy Ter Avest, Kioa L. Wijnsma, Caroline Duineveld, Rob ter Heine, Elena B. Volokhina, Lambertus P. W. J. Van Den Heuvel, Jack F. M. Wetzels, Nicole C. A. J. van de Kar   +8 more
doaj   +1 more source

Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series

Brain Sciences, 2021
(1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on
Marco Allinovi, Angelo Bellinvia, Francesco Pesce, Sabrina Milan Manani, Lorenzo Razzolini, Brigida Brezzi, Paolo Protopapa, Vittorio Mantero, Leonardo Caroti, Calogero Lino Cirami, Maria Pia Amato, Lucia Del Vecchio   +11 more
doaj   +1 more source

Eculizumab‐related drug reaction in a patient with neuromyelitis optica

Clinical Case Reports, 2023
Eculizumab is approved for treatment of antibody positive neuromyelitis optica, myasthenia gravis, and hematologic disorders like paroxysmal nocturnal hemoglobinuria. Drug rash has not yet been reported as a side effect of eculizumab. We report a case of
Rishi Sharma, Moises Romo, Flavia Nelson
doaj   +1 more source

Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort

PLoS ONE, 2021
Background Atypical Hemolytic Uremic Syndrome (aHUS) is an ultra-rare disease that potentially leads to kidney graft failure due to ongoing Thrombotic Microangiopathy (TMA).
Hong Si Nga, Lilian Monteiro Pereira Palma, Miguel Ernandes Neto, Ida Maria Maximina Fernandes-Charpiot, Valter Duro Garcia, Roger Kist, Silvana Maria Carvalho Miranda, Pedro Augusto Macedo de Souza, Gerson Marques Pereira, Luis Gustavo Modelli de Andrade   +9 more
doaj   +2 more sources

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

PLoS ONE, 2020
IntroductionEculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk.
Catherine H Bozio, Cheryl Isenhour, Lucy A McNamara   +2 more
doaj   +1 more source

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

Frontiers in Neurology, 2021
Objective: To investigate the pharmacokinetics and pharmacodynamics of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods ...
Pratap Singh, Xiang Gao, Huub Jan Kleijn, Francesco Bellanti, Ryan Pelto   +4 more
doaj   +1 more source

Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin–Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial

Journal of the American Society of Nephrology, 2023
Visual Abstract Significance Statement Shiga toxin–related hemolytic uremic syndrome (STEC-HUS) is a serious condition, characterized by multiorgan thrombotic microangiopathy, mainly affecting children.
A. Garnier, K. Brochard, T. Kwon, A. Sellier-Leclerc, A. Lahoche, Emma Allain Launay, F. Nobili, M. Caillez, S. Taque, J. Harambat, Guylhene Michel-Bourdat, V. Guigonis, M. Fila, S. Cloarec, D. Djamal-Dine, Loïc de Parscaux, Lise Allard, R. Salomon, T. Ulinski, V. Frémeaux-Bacchi, Christophe Morin, P. Olivier‐Abbal, H. Colineaux, F. Auriol, C. Arnaud, I. Kieffer, Clara Brusq   +26 more
semanticscholar   +1 more source